本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Caris Life Sciences, Inc.

24.34
+0.30001.25%
盤後24.340.00000.00%19:39 EDT
成交量:182.30萬
成交額:4,448.94萬
市值:68.67億
市盈率:65.43
高:24.67
開:24.16
低:24.09
收:24.04
52周最高:34.75
52周最低:14.19
股本:2.82億
流通股本:1.16億
量比:0.42
換手率:1.57%
股息:- -
股息率:- -
每股收益(TTM):0.3720
每股收益(LYR):-3.2200
淨資產收益率:20.13%
總資產收益率:8.77%
市淨率:11.61
市盈率(LYR):-7.56

資料載入中...

2025/11/05

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/11/05

重要事件披露

Form 8-K - Current report
2025/10/30

重要事件披露

Form 8-K - Current report
2025/08/13

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/08/13

重要事件披露

Form 8-K - Current report
2025/06/20

重要事件披露

Form 8-K - Current report
2025/06/18

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/06/16

[修訂]招股説明書

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
2025/06/14

SEC問詢函

Form CORRESP - Correspondence
2025/06/14

SEC問詢函

Form CORRESP - Correspondence
2025/06/09

[修訂]招股説明書

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
2025/05/24

招股説明書

Form S-1 - General form for registration of securities under the Securities Act of 1933
2021/06/29

超過5%披露

SC 13D - General statement of acquisition of beneficial ownership
2021/06/21

重要事件披露

8-K - Current report
2021/06/08

重要事件披露

8-K - Current report
2021/05/26

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/04/30

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2021/04/30

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/04/29

重要事件披露

8-K - Current report
2021/03/01

年度報告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]